News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mirada Medical Makes Bold Challenge at Radiological Society of North America (RSNA), Brings MR/PET to Everyone



11/23/2011 8:54:22 AM

OXFORD, UNITED KINGDOM--(Marketwire - November 23, 2011) - In a further demonstration of the company's belief that "MR/PET is now within reach of everyone", Mirada Medical has issued a bold challenge to demonstrate their software MR/PET technology "live" on any site's data at the 2011 Radiological Society of North America (RSNA) meeting being held in Chicago (booth # 8722) November 27 through December 1. Mirada, recognized as an industry leader in Software MR/PET, asserts that MR/PET is now available to anyone wishing to combine the unique benefits of these two powerful imaging technologies to provide superior patient care. To support that vision, Mirada has developed a unique software MR/PET solution based on its validated deformable registration technology.

To show the ease, quality and clinical benefit of Mirada's software MR/PET solution, the company is offering to demonstrate their product in real time on their RSNA exhibit using imaging data brought by attendees from around the world. The data can be from any DICOM compliant MR, PET, or PET/CT system, regardless of the manufacturer, and must be anonymized and compliant for this use under protected health information standards. Physicians wishing to participate in the RSNA demonstration can register at Mirada's web site: www.mirada-medical.com/BYOMRPET.

"We are seeing an ever growing interest in MR/PET fusion, said Timor Kadir, Chief Science Officer for Mirada Medical."Our software MR/PET solution makes it practical and offers the clinical benefits of hybrid MR/PET scanners at a fraction of the cost ."

Also showcased at Mirada's exhibit will be the company's innovative workflow solution for tumor board called Casemeeting. Tumor board meetings constitute an IT headache for the radiologist who is often expected to present and review multiple detailed cancer cases in a very short period of time. Making all the images available at the meeting can be problematic and this problem is compounded by the need to organize them into a cohesive presentation. Having all the software tools available to rapidly show and discuss detailed findings for each case was until now nearly impossible. Casemeeting however makes easy work of preparing for and presenting at tumor board meetings. Automatically, it turns the radiologist's key imaging into slides and sorts them into a short presentation for each patient to be reviewed. The presenter can change the order or remove slides. Most innovative of all, it also allows the presenter to press a button on the screen and instantly return live to the exact same place in the original reading software where the key image was taken, allowing the case to be reviewed in detail by the other clinicians in attendance. Casemeeting solves the problem of efficiently preparing cases and presenting them at tumor board.

Mirada will be demonstrating many other advanced applications on its XD3 technology platform, including: Quantitative Response Assessment which allows the user to simultaneously read and quantify an unlimited number of studies acquired over any time period. Mirada provides native support for RECIST, PERCIST and WHO and the system can be customized to support customer specific treatment response analysis protocols regardless of how many follow up studies are required. Mirada's latest and most powerful CT Lesion Segmentation technology allows a reading clinician to quickly and accurately segment a lesion in a CT scan for the purpose of comparing size, volume and tissue characteristics between scans. This will also support faster and more accurate RECIST type response assessment protocols.

About Mirada Medical
Mirada Medical is an internationally recognised brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.

Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis. Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings such as tumor board.

Mirada Medical, Mirada XD3, Caseaccess and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information, visit www.mirada-medical.com
Mirada Medical Build Your Own MR/PET Press Release
http://hugin.info/143183/R/1565985/486143.pdf


For more information, please contact:

Mirada Medical
US/Worldwide:
Robert Ripley
tel: (440) 591-8638
Insource Communications
rripley@insourceinc.com
enquiries@mirada-medical.com
www.mirada-medical.com

UK Office:
Oxford Center for Innovation
New Road, Oxford
OX1 1BY
United Kingdom
Tel: +44(0)1865 261410


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES